Vanguard Asset Management’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.32M Buy
68,650
+3,859
+6% +$152K ﹤0.01% 1485
2026
Q2
$2.5M Sell
64,791
-4,651
-7% -$142K ﹤0.01% 1449
2026
Q1
$1.72M Buy
+69,442
New +$1.8M ﹤0.01% 1531

Other funds holding IMVT

Vanguard Asset Management's IMVT Position: Q3 2026 in Review

Vanguard Asset Management increased its Immunovant (IMVT) stake by 6% in Q3 2026, buying an estimated $152K and bringing the position to 68,650 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1485.

Vanguard Asset Management first reported a position in IMVT in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.5M in Q2 2026. 232 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Vanguard Asset Management held 68,650 shares of Immunovant worth $2.32M as of Q3 2026.
  • Vanguard Asset Management bought 3,859 Immunovant shares in Q3 2026, an estimated $152K.
  • Immunovant made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1485 holding.
  • Vanguard Asset Management first reported a position in Immunovant in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's Immunovant position peaked at $2.5M in Q2 2026.
  • 232 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.